Logo image of IPSC

CENTURY THERAPEUTICS INC (IPSC) Stock Fundamental Analysis

NASDAQ:IPSC - Nasdaq - US15673T1007 - Common Stock - Currency: USD

0.5073  -0.02 (-4.14%)

After market: 0.5135 +0.01 (+1.22%)

Fundamental Rating

3

IPSC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 551 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for IPSC as it has an excellent financial health rating, but there are worries on the profitability. IPSC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year IPSC has reported negative net income.
In the past year IPSC has reported a negative cash flow from operations.
In the past 5 years IPSC always reported negative net income.
In the past 5 years IPSC reported 4 times negative operating cash flow.
IPSC Yearly Net Income VS EBIT VS OCF VS FCFIPSC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

IPSC has a Return On Assets of -6.89%. This is amongst the best in the industry. IPSC outperforms 86.57% of its industry peers.
IPSC has a better Return On Equity (-9.04%) than 88.57% of its industry peers.
Industry RankSector Rank
ROA -6.89%
ROE -9.04%
ROIC N/A
ROA(3y)-33.55%
ROA(5y)-34.54%
ROE(3y)-65.22%
ROE(5y)-58.59%
ROIC(3y)N/A
ROIC(5y)N/A
IPSC Yearly ROA, ROE, ROICIPSC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

IPSC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IPSC Yearly Profit, Operating, Gross MarginsIPSC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

7

2. Health

2.1 Basic Checks

IPSC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IPSC has been increased compared to 1 year ago.
IPSC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IPSC Yearly Shares OutstandingIPSC Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M 80M
IPSC Yearly Total Debt VS Total AssetsIPSC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

IPSC has an Altman-Z score of -2.13. This is a bad value and indicates that IPSC is not financially healthy and even has some risk of bankruptcy.
IPSC has a Altman-Z score of -2.13. This is comparable to the rest of the industry: IPSC outperforms 52.81% of its industry peers.
IPSC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.13
ROIC/WACCN/A
WACC11.13%
IPSC Yearly LT Debt VS Equity VS FCFIPSC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

IPSC has a Current Ratio of 11.70. This indicates that IPSC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 11.70, IPSC belongs to the top of the industry, outperforming 82.58% of the companies in the same industry.
A Quick Ratio of 11.70 indicates that IPSC has no problem at all paying its short term obligations.
IPSC has a Quick ratio of 11.70. This is amongst the best in the industry. IPSC outperforms 82.94% of its industry peers.
Industry RankSector Rank
Current Ratio 11.7
Quick Ratio 11.7
IPSC Yearly Current Assets VS Current LiabilitesIPSC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

2

3. Growth

3.1 Past

IPSC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 86.88%, which is quite impressive.
IPSC shows a strong growth in Revenue. In the last year, the Revenue has grown by 8268.46%.
EPS 1Y (TTM)86.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%297.78%
Revenue 1Y (TTM)8268.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%12667.72%

3.2 Future

Based on estimates for the next years, IPSC will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.51% on average per year.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y83%
EPS Next 2Y5.67%
EPS Next 3Y3.58%
EPS Next 5Y15.51%
Revenue Next Year3161.86%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

IPSC Yearly Revenue VS EstimatesIPSC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2030 2031 2032 20M 40M 60M 80M 100M
IPSC Yearly EPS VS EstimatesIPSC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IPSC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IPSC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IPSC Price Earnings VS Forward Price EarningsIPSC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IPSC Per share dataIPSC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.67%
EPS Next 3Y3.58%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IPSC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CENTURY THERAPEUTICS INC

NASDAQ:IPSC (8/8/2025, 8:00:02 PM)

After market: 0.5135 +0.01 (+1.22%)

0.5073

-0.02 (-4.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)10-27 2025-10-27/bmo
Inst Owners50.61%
Inst Owner Change-0.4%
Ins Owners1.44%
Ins Owner Change2.28%
Market Cap43.71M
Analysts83.33
Price Target4.49 (785.08%)
Short Float %2.19%
Short Ratio1.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)743.28%
Min EPS beat(2)0.1%
Max EPS beat(2)1486.45%
EPS beat(4)4
Avg EPS beat(4)381.21%
Min EPS beat(4)0.1%
Max EPS beat(4)1486.45%
EPS beat(8)5
Avg EPS beat(8)189.49%
EPS beat(12)8
Avg EPS beat(12)127.98%
EPS beat(16)9
Avg EPS beat(16)73.23%
Revenue beat(2)2
Avg Revenue beat(2)226.08%
Min Revenue beat(2)115.99%
Max Revenue beat(2)336.16%
Revenue beat(4)2
Avg Revenue beat(4)82.4%
Min Revenue beat(4)-61.68%
Max Revenue beat(4)336.16%
Revenue beat(8)2
Avg Revenue beat(8)3.92%
Revenue beat(12)5
Avg Revenue beat(12)10.2%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-8.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.56%
EPS NY rev (1m)0%
EPS NY rev (3m)74.21%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)0%
Revenue NY rev (3m)81.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.38
P/FCF N/A
P/OCF N/A
P/B 0.18
P/tB 0.21
EV/EBITDA N/A
EPS(TTM)-0.29
EYN/A
EPS(NY)-1.44
Fwd EYN/A
FCF(TTM)-1.33
FCFYN/A
OCF(TTM)-1.33
OCFYN/A
SpS1.33
BVpS2.79
TBVpS2.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.89%
ROE -9.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.55%
ROA(5y)-34.54%
ROE(3y)-65.22%
ROE(5y)-58.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.67%
Cap/Sales 0.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.7
Quick Ratio 11.7
Altman-Z -2.13
F-Score4
WACC11.13%
ROIC/WACCN/A
Cap/Depr(3y)156.34%
Cap/Depr(5y)541.5%
Cap/Sales(3y)401.8%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)86.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%297.78%
EPS Next Y83%
EPS Next 2Y5.67%
EPS Next 3Y3.58%
EPS Next 5Y15.51%
Revenue 1Y (TTM)8268.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%12667.72%
Revenue Next Year3161.86%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y76.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.82%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y13.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.6%
OCF growth 3YN/A
OCF growth 5YN/A